Jan 12 (Reuters) - Merus NV 2GH.F:
MERUS AND BIOHAVEN ANNOUNCE COLLABORATION TO CO-DEVELOP THREE NOVEL BISPECIFIC ADC PROGRAMS
BIOHAVEN LTD - CO IS RESPONSIBLE FOR PRECLINICAL ADC GENERATION OF THREE MERUS BISPECIFIC ANTIBODIES UNDER MUTUALLY AGREED RESEARCH PLANS
BIOHAVEN - AGREEMENT INCLUDES TWO MERUS BISPECIFIC PROGRAMS GENERATED USING BICLONICS PLATFORM
BIOHAVEN LTD - MERUS WILL RECEIVE AN UPFRONT PAYMENT AND LICENSE FEE AT ADC CANDIDATE NOMINATION OF FIRST PROGRAM
Source text: ID:nGNX47y28G
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。